Hirschsprung disease
Conditions
Interventions
Intervention group:Routine perioperative management plus perioperative microecological combined intervention, including live combined Bifidobacterium-Lactobacillus tablets, Clostridium butyricum powde
Control group:Routine perioperative management, including preoperative bowel preparation, perioperative antibiotic-based treatment, anesthesia and surgical management, intravenous nutritional support,
Sponsors
shanghai Children’s Medical Center Guizhou Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
0.2 Years to 10 Years
Inclusion criteria
Inclusion criteria: 1.Definitive diagnosis: The patient must have a confirmed diagnosis of Hirschsprung's disease established by a physician. 2.Age range: Participants must be within a specified age range (e.g., >1 year of age) to ensure homogeneity of the study population. 3.Surgical plan: The patient must have a clear surgical plan and be scheduled to undergo surgery in the near future. 4.Parental/guardian consent: Written informed consent must be obtained from the parent or legal guardian of all children to allow participation in this study. For children over 8 years of age, the child's own assent must also be obtained, and the child must sign the informed consent form. Written informed consent obtained from the guardians.
Exclusion criteria
Exclusion criteria: 1.Other serious diseases: Patients with other serious diseases besides Hirschsprung's disease, such as congenital heart disease or immune system disorders, which may 2.Prior treatment: Patients who have received treatments that may affect the gut microbiota or immune system within the recent period. 3.Inability to comply with the study: Parents or guardians who are unable or unwilling to cooperate with study requirements, such as sample collection and data recording. 4.Known allergy to study drugs or treatments: If the study involves specific drugs or therapies, patients with known allergies to these drugs or therapies will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Hirschsprung-associated enterocolitis within 6 months after surgery;Changes in gut microbiota diversity and relative abundance of major genera; | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of postoperative hospital stay;Changes in perioperative inflammatory and immune indices; | — |
Countries
China
Contacts
Public ContactZhuang Yize
shanghai Children’s Medical Center Guizhou Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed